MedTrace Logo

IL-6 Inhibition for Modulating Inflammation After Cardiac Arrest

NCT03863015 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2020-08-21

No results posted yet for this study

Summary

Resuscitated cardiac arrest is associated with a systemic inflammatory response that is directly associated with poor prognosis. Inhibition of the IL-6 mediated immune response may potentially inhibit the systemic inflammatory response, potentially improving the prognosis of these severely ill patients.

Conditions

  • Heart Arrest
  • Out-Of-Hospital Cardiac Arrest
  • Systemic Inflammatory Response Syndrome

Interventions

DRUG

Tocilizumab 20 Mg/mL Intravenous Solution

Tocilizumab is suspended in isotonic saline to a total volume of 100mL prior to infusion

DRUG

isotonic saline

A one hour infusion of 100mL isotonic saline

Sponsors & Collaborators

  • Christian Hassager

    lead OTHER

Principal Investigators

  • Christian Hassager, MD, DMSc · Department of Cardiology, The Heart Center, Rigshospitalet, Copenhagen, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-04
Primary Completion
2019-12-23
Completion
2020-06-30

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03863015 on ClinicalTrials.gov